Helix BioPharma Cash Flow Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Net Income	-	-5.21	-9.26	-6.29	-6.56	-8.04
Depreciation & Amortization	0	0.01	0.01	0.01	0.01	0.2
Stock-Based Compensation	0.02	0.18	3.52	0.57	0.43	0.66
Other Adjustments	0.1	-0.15	0.03	-0.01	0.51	-1.45
Change in Receivables	-0.01	-0.07	0.01	0.22	0.07	-0.17
Changes in Accounts Payable	-0.13	1.3	0.67	-0.11	-0.87	0.05
Changes in Accrued Expenses	-	-	-	0.04	-0.04	0.08
Changes in Other Operating Activities	0.13	0.1	-0.19	0.04	-0.06	-0.64
Operating Cash Flow	-3.21	-3.83	-5.22	-5.53	-6.51	-9.3
Capital Expenditures	-	-0	-0.01	-0.01	-	-
Sale of Property, Plant & Equipment	-	0.02	-	0.01	-	-
Proceeds from Business Divestments	-	-	-	-	-	2.02
Investing Cash Flow	-	0.02	-0.01	-0.01	-	2.02
Long-Term Debt Issued	-	-	-	-	-	3.16
Long-Term Debt Repaid	-	-	-	-2.06	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-	-2.06	-	3.16
Issuance of Common Stock	3.3	2.8	5.51	4.15	6.21	3.56
Net Common Stock Issued (Repurchased)	3.3	2.8	5.51	4.15	6.21	3.56
Other Financing Activities	-	-	-	1	-	-0.16
Financing Cash Flow	5.32	2.8	5.51	3.09	6.21	6.56
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-0.01	0.05
Net Cash Flow	2.11	-1.02	0.27	-2.44	-0.31	-0.67
Free Cash Flow	-3.21	-3.83	-5.23	-5.54	-6.51	-9.3
Free Cash Flow Per Share	-0.04	-0.07	-0.12	-0.14	-0.20	-0.35
Levered Free Cash Flow	-3.17	-3.52	-8.69	-8.38	-7.52	-5.19
Unlevered Free Cash Flow	-3.18	-3.85	-8.71	-6.35	-7	-9.44